Stockreport

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics, Inc.  (LENZ) 
PDF VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad prod [Read more]